Analysts Miffed By Vertex’s Lack Of Transparency With CF Combo Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex Pharmaceuticals presented top-line data for its drug combination in cystic fibrosis, but analysts are wondering why the company was not forthcoming about the full data set.
You may also be interested in...
With Final Data Unveiled, Vertex Will Move Its CF Combo Into Pivotal Trials In 2013
Despite controversies about incorrectly reported data and allegations of incomplete data, Vertex has demonstrated lung function benefit for a combination of Kalydeco and VX-809 in Phase II and will move the combination into Phase III trials early next year.
Kalydeco Passed FDA’s Approval Test With The Help Of A Failed Study
FDA’s speedy approval of Vertex’s disease-modifying, genetically targeted cystic fibrosis treatment ivacaftor appears to have been made easier by the company’s failure to show efficacy in a population with a different genetic mutation. The failed study not only had important implications for preventing off-label use, it added considerably to the safety database in an orphan indication.
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year
Kalydeco, an oral CFTR potentiator, becomes the first approved drug to address the underlying cause of cystic fibrosis, rather than just treating the disease’s symptoms.